Module now available Long-read sequencing analysis See the research
FDA Breakthrough
Device Designation

Patho-Seq

Introducing Patho-Seq

A new combination of sequencing protocol and RipSeq technologies, adapted to meet FDA's specific requirements for approval for clinical use.

Patho-Seq will not be available for sale until it has received FDA marketing approval. If you wish to use Pathogenomix's current technologies for research-only purposes, please check out our current product, RipSeq.

Why sequencing

A rapid, hypothesis-free diagnostic

Patho-Seq is designed for the rapid detection and identification of hundreds of clinically relevant bacteria for a broad list of clinical conditions and sample types, including sepsis from whole blood samples and bacterial meningitis from CSF.

No hypothesis required

A broad diagnostic that can identify any of thousands of pathogens from a single test. Clinicians using other pathogen diagnostics need a strong hypothesis in order to select the correct growth medium or NAAT.

At least 48 hours faster

For the many difficult-to-culture bacteria, results arrive at least 48 hours faster than the currently approved standard-of-care tests.

Poly-microbial and pre-treated samples

The ability to identify poly-microbial infections, and to identify pathogens in the frequent case where the patient has already been treated with antimicrobials.

More complete results

More complete results than traditional culture, and more complete results than traditional culture followed by LC/MS.

Regulatory status

Granted FDA Breakthrough Device Designation

The FDA has granted Patho-Seq a Breakthrough Device Designation due to its significant advantages compared to current FDA-approved methods for the diagnosis of pathogenic bacteria in cases where infection may threaten life or long-term health.

Through the Breakthrough Device Program, FDA provides Pathogenomix with continued guidance and accelerated review for its subsequent De Novo approval process. Pathogenomix collaborated with Mayo Clinic on the development of the techniques and data which supported the application.

Designation granted for the identification of infectious bacteria from

  • Sepsis and bacteremia
  • Bacterial meningitis
  • Joint and implant infections
  • Tick-borne bacterial infections

The clinical need

Infections where the cause is never identified

13.9%

of all hospital admissions in 2018 were for infections with a likely bacterial organism.

70%+

of 2.5 million sepsis cases studied in which the causative organism was never identified.

200,000

deaths and over 2 million hospital admissions caused by sepsis alone in 2018.

$16k–38k

mean medical cost per sepsis patient ($16,324 to $38,298).

Figures as cited in the Pathogenomix press release of January 19th 2022. Read the release.

Patho-Seq NGS

Remarkably fast, designed to save you time

Using our novel algorithms, Patho-Seq will process your targeted NGS sequence file locally and reduce the information needed to upload by a factor of 1000:1, while still retaining resolution and specificity. This means no lengthy file upload, and no costly big data file storage.

All this in less than five minutes, including reporting.

Patho-Seq DB

The best microbial database there is

After upload, the cloud-based Patho-Seq will analyze the uploaded reads against any of our curated Patho-Seq DB databases, no matter the target.

Patho-Seq combines a sequencing protocol with RipSeq technologies. Read more about RipSeq DB.

Inquiries regarding Patho-Seq

Talk to Paul Robertson

For any questions about Patho-Seq, call +1 650 218 4189 or send an email.